

Non-Antibiotics: Psychotropic Drugs

Sadik Kalayci*

Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Turkey

*Corresponding Author: Sadik Kalayci, Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Turkey.

Received: June 29, 2017; Published: July 24, 2017

In the 1950s, it was found that many drugs designed for non-infectious diseases can also exhibit antimicrobial properties [1]. These drugs are named as non-antibiotics in pharmacology [2,3]. Figure 1 demonstrates the action of non-antibiotics.



Figure 1: The concept of non-antibiotics [3].

The actions of non-antibiotic drugs on microbial growth are different. They can show direct antimicrobial activity by increasing the efficiency of an antibiotic when they are given together (Synergistic effect), or change the pathogenicity of microorganisms or activity on the physiology such as modulating macrophage activity [4].

Among the non-antibiotics, the most studied ones are psychotropic drugs. These psychotropic drugs not only reverse microbial antibiotic resistance but also exhibit direct antimicrobial activity against several biological targets [5].

In 1975, the antimicrobial activity of psychotropic drugs was described. At that time, antibacterial activity of series psychotropic drugs sertraline, paroxetine, fluoxetine and clomipramine was examined against the anaerobic fecal bacteria using agar diffusion and minimum inhibitory concentration (MIC) test. Among them, the phenothiazines and amitriptyline showed antibacterial activity in the MIC's test in the 40 - 640 µg/ml concentration range [6].

Since then, a lot of psychotropic drugs have been examined. The drugs have a significant antimicrobial activity, mainly against Grampositive bacteria, some against Gram-negative bacteria, Mycobacterium, Yeast and Fungi [5]. Selective serotonin reuptake inhibitors (SSRI) are used widely for the treatment of depression, of chronic pain, menopausal symptoms, and migraine headache prophylaxis [7]. Sertraline is a potent selective serotonin reuptake inhibitors, approved for the treatment of depression, Social phobia, obsessive compulsive, panic and post traumatic disorders [8].

In previous study, sertraline displayed the strongest and widest range of antimicrobial activities against all bacteria, yeast and fungi except *Pseudomonas aeruginosa*. Sertraline but also other psychotropic drugs have been interestingly found to be inactive against *P. aeruginosa* [5].

One scenario to this situation might be that *P. aeruginosa* has protective outer membrane efflux pumps which prevent bacteria from high concentrations of antimicrobial agents accumulation inside the cytoplasm or low outer membrane permeability controlled by the OprD porin production [9].

Interestingly, SSRI group drugs (sertraline, paroxetine, and fluoxetine) and clomipramine exhibited better antibacterial activity against vancomycin resistant enterococci (VRE) compared to parental *Enterococcus faecalis* strain.

In contrast to this observation MRSA(Methicillin-resistant *Staphylococcus aureus*) was more resistant to chemicals tested with respect to parental *Staphylococcus aureus*.

Mycobacterium tuberculosis has been the most sensitive against psychotropic drugs including sertraline, paroxetine, fluoxetine and clomipramine. The drugs were found to display inhibitory effect as low concentration as maximum psychotropic drug serum levels in human metabolism which is close to 2 mg/L.

It is suggested that *in vivo* studies should be conducted to examine potential antimycobacterial activities of the psychotropic drugs alone or in combination with approved tuberculosis drugs [5].

The main limiting factor for the use of non-antibiotic drugs as an antimicrobial agent in mammalian system is that the maximum level in serum remains (approx. 1 mg/L) lower than the concentration required for inhibition of microbial growth [10].

These studies suggest that the use of psychotropic drugs even low concentration, alone or in combination with other antimicrobials can be effective against various type of microorganisms.

Bibliography

- Williams JD. "The Garrod lecture. Selective toxicity and concordant pharmacodynamics of antibiotics and other drugs". *Journal of Antimicrobial Chemotherapy* 35.6 (1995): 721-737.
- 2. Amaral L and Kristiansen JE. "Phenothiazines: an alternative to conventional therapy for the initial management of suspected multidrug resistant tuberculosis. A call for studies". *International Journal of Antimicrobial Agents* 14.3 (2000): 173-176.
- Kristiansen JE. "The antimicrobial activity of psychotropic drugs and stereo-isomeric analogues (Thesis, Dr. sci. University of Copenhagen, Denmark)". Danish Medical Bulletin 37.2 (1990): 165-182.
- 4. Martins M., *et al.* "Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities". *International Journal of Antimicrobial Agents* 31.3 (2008): 198-208.
- 5. S Kalaycı, *et al.* "Antimicrobial properties of various psychotropic drugs against broad range microorganisms". *Current Psychopharmacology* 3 (2014): 195-202.
- 6. Brown MW. "In vitro antibacterial activity of drugs against human intestinal anaerobic bacteria". *Journal of Pharmaceutical Sciences* 64.4 (1975): 700-702.

Citation: Sadik Kalayci. "Non-Antibiotics: Psychotropic Drugs". EC Microbiology 10.1 (2017): 19-21.

Non-Antibiotics: Psychotropic Drugs

- 7. Bahl S., *et al.* "Use of antidepressant medications and the possible asso- ciation with breast cancer risk. A review". *Psychotherapy and Psychosomatics* 72.4 (2003): 185-194.
- 8. DeVane CL., et al. "Clinical pharmacokinetics of sertraline". Clinical Pharmacokinetics 41.15 (2002): 1247-1266.
- 9. Poole K. "Bacterial multidrug resistance-emphasis on efflux mechanisms and Pseudomonas aeruginosa". *Clinical Pharmacokinetics* 34.4 (1994): 453-456.
- 10. Munoz-Bellido J., *et al.* "Antimicrobial activity of psychotropic drugs: selective serotonin reuptake inhibitors". *International Journal of Antimicrobial Agents* 14.3 (2000): 177-180.

Volume 10 Issue 1 July 2017 ©All rights reserved by Sadik Kalayci.